University College London/University of Gothenburg PhD course “Biomarkers in neurodegenerative diseases” 2019—course organisation
Abstract Biomarkers are increasingly employed for effective research into neurodegenerative diseases. They have become essential for reaching an accurate clinical diagnosis, monitoring disease, and refining entry criteria for participation in clinical treatment trials, and will be key in measuring target engagement and treatment outcome in disease-modifying therapies. Emerging techniques and research combining different biomarker modalities continue to strengthen our understanding of the underlying pathology and the sequence of pathogenic events. Given recent advances, we are now at a pivotal stage in biomarker research. PhD students working in the field of neurodegenerative disease require a working knowledge of a range of biomarkers available and their limitations, to correctly interpret scientific literature and to design and conduct successful research studies themselves. Here, we outline the University College London/University of Gothenburg “Biomarkers in neurodegenerative diseases course”, the first initiative of its kind aimed to bring together both experts and PhD students from all areas within the field of neurodegeneration, to provide comprehensive knowledge of biomarker research for the next generation of scientists..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Alzheimer's research & therapy - 12(2020), 1 vom: 04. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khatun, Ayesha [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Amyloid |
|---|
| Anmerkungen: |
© The Author(s). 2020 |
|---|
| doi: |
10.1186/s13195-020-0583-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR031008909 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR031008909 | ||
| 003 | DE-627 | ||
| 005 | 20230519164348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13195-020-0583-z |2 doi | |
| 035 | |a (DE-627)SPR031008909 | ||
| 035 | |a (SPR)s13195-020-0583-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khatun, Ayesha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a University College London/University of Gothenburg PhD course “Biomarkers in neurodegenerative diseases” 2019—course organisation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s). 2020 | ||
| 520 | |a Abstract Biomarkers are increasingly employed for effective research into neurodegenerative diseases. They have become essential for reaching an accurate clinical diagnosis, monitoring disease, and refining entry criteria for participation in clinical treatment trials, and will be key in measuring target engagement and treatment outcome in disease-modifying therapies. Emerging techniques and research combining different biomarker modalities continue to strengthen our understanding of the underlying pathology and the sequence of pathogenic events. Given recent advances, we are now at a pivotal stage in biomarker research. PhD students working in the field of neurodegenerative disease require a working knowledge of a range of biomarkers available and their limitations, to correctly interpret scientific literature and to design and conduct successful research studies themselves. Here, we outline the University College London/University of Gothenburg “Biomarkers in neurodegenerative diseases course”, the first initiative of its kind aimed to bring together both experts and PhD students from all areas within the field of neurodegeneration, to provide comprehensive knowledge of biomarker research for the next generation of scientists. | ||
| 650 | 4 | |a Neurodegenerative diseases |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Biomarkers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tau |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Amyloid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Positron emission tomography |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Magnetic resonance imaging |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cerebrospinal fluid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Blood biomarkers |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Paterson, Ross W. |4 aut | |
| 700 | 1 | |a Schöll, Michael |0 (orcid)0000-0001-7800-1781 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's research & therapy |d London : BioMed Central, 2009 |g 12(2020), 1 vom: 04. Feb. |w (DE-627)SPR030810736 |w (DE-600)2506521-X |x 1758-9193 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:1 |g day:04 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13195-020-0583-z |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 1 |b 04 |c 02 | ||